Galapagos Stock News

Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of the Company.

Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

Galapagos has managed to curtail its R&D and G&A expenses, demonstrating efficient cost management. The company has strategically focused on oncology and immunology, sectors with high unmet medical needs and market impact potential. Galapagos is investing in CAR-T cell therapies, with promising early data indicating progress in its unique manufacturing platform.

Galapagos NV (GLPG) Q4 2023 Earnings Call Transcript

Full year 2023 key financials : Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023 Operational cash burn i of €414.8 million, within guidance 2023 and year-to-date key updates : Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A. Achieved encouragi...

Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies

Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business to Alfasigma S.p.A.

Mechelen, Belgium; 4 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific, Inc. (NYSE: TMO) (“Thermo Fisher”) for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco area.